During the temporary suspension of Bharat Biotech’s deal with Brazil for over 20 million doses of the Covaxin COVID vaccine, the pharmaceutical company has clarified about and it had not received any payment from the government of Brazil till now.
“As of the 29th June 2021, Bharat Biotech has not received any advance payments nor supplied any vaccines to Ministry of Health Brazil,” statement delivered.
As per PTI news agency reports the pricing of the doses done by the company it said, “The pricing of Covaxin has been clearly established between $15-20 per dose for supplies to governments outside India. The pricing for Brazil has been indicated at $15 per dose.”
Besides this, two testimonies by whistleblowers before a parliamentary panel blamed on President Jair Bolsonaro and his powerful coalition chief for agreeing to buy the Indian vaccine at a price that was allegedly higher than that of other options available in the market also when it lacked local regulatory approval.
As per the Reuters report, the company stated, “We strongly refute and deny any kind of allegation or implication of any wrongdoing whatsoever with respect to the supply of Covaxin.” The company also mentioned that Madison Biotech was its global sales and marketing unit.
Regarding this the health minister tweeted that, “According to CGU’s preliminary analysis, there are no irregularities in the contract, but, due to compliance, the @minsaude opted to suspend the contract for further analysis.”